12-22-06

+

10533144 - GAU 6554

Please type a plus sign (+) inside this box →

PTO/SB/21 (05-03)
Approved for use through 04/30/2003. OMB 0651-0031
and Trademark Office; U.S. DEPARTMENT OF COMMERCE

	U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.										
	E	Application Number	10/533,144								
D.	"installer	Filing Date	April 24, 2006								
ľ	RANSMITTA	DEC 2 0 2006 Einst Named Inventor	MASUDA, ESTEBAN								
(	FORM '	Group Art Unit	1654								
13	MT&TRN(ID be used for all correspondence after in	initial filing) ADEMATH. Examiner Name	Not yet assigned								
	Total Number of Pages in This Submis	Attorney Docket Number	RIGL-023								
		ENCLOSURES (check all that apply)									
	Fee Transmittal Form	Assignment Papers (for an Application)	After Allowance Comminication to Group								
	Amendment / Reply	Drawing(s)	Appeal Communication to Board of Appeals and Interferences								
	After Final	Licensing-related Papers  Petition	Appeal Communication to Group (Appeal Notice, Brief, Reply Brief)								
•	Affidants/declaration(s)  Extension of Time Request  Express Abandonment Request  Supplemental Information Disclosure Statement  Certified Copy of Priority Documents  Response to Missing Parts/ Incomplete Application  Response to Missing Parts under 37 CFR 1.52 or 1.53	Petition to Convert to a Provisional Application Power of Attorney, Revocation Change of Correspondence Address Terminal Disclaimer Request for Refund CD, Number of CD(s	Proprietary information  Status Letter  Other Enclosure(s) (please identify below): Form PTO/SB/08A 3 references: Kinsella at al. Craik et al. Supplementary European Search Report Return postcard								
	SIGNA	ATURE OF APPLICANT, ATTORNEY, OR	RAGENT								
	Signing Attorney/Agent (Reg. No.)  Signature  JAMES S. KEDDIE, PH.D., 48,920 BOZ EVIC, FIELD & SRANGS, LLP										
	Date December 20, 200	96									
	EXPRESS MAIL LABEL NO. EV 687 640 743 US										

This collection of Information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USEPT to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.4. This collection is estimated to 12 minutes to complete, including qualifering, preparing, and authoriting the complete including qualifering preparing, and authoriting the observable of the complete including the complete including the complete including the complete including this burden, subdot to sent to the Chief Information Officer, U.S. Patient and Tademark Office, U.S. Department of Commerce, P.O. Box 1450, Mexandria, V.A. 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patients, P.O. Box 1450, Mexandria, V.A. 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Alexandria, VA 22313-1450

## Express Mail No. EV 687 640 743 US

Empress Man No. E. V. Co. V. I. C. E.						
SUPPLEMENTAL	Attorney Docket	RIGL-023				
INFORMATION	First Named Inventor	MASUDA, ESTEBAN				
DISCLOSURE STATEMENT	Application Number	10/533,144				
UNDER 37 C.F.R. § 1.97(e)	Confirmation No.	5373				
STEE	Filing Date	April 24, 2006				
21	Group Art Unit	1654				
Address to: DEC 2 0 2006	Examiner Name	Not yet assigned				
Commissioner for Patents P.O. Box 1450		F SCREENING CYCLIC PEPTIDES SYING TARGETS THEREFOR"				

Sir:

Applicants submit herewith patents and/or publications which may be material to the examination of this application and in respect of which there may be a duty to disclose in accordance with 37 C.F.R. § 1.56. While this Statement may be "material" pursuant to 37 C.F.R. § 1.56, it is not intended to constitute an admission that any patent, publication, or other information referred to therein is "prior art" for this invention unless specifically designated as such. A listing of patents and/or publications is shown on enclosed Form PTO-SB/08A and a copy of each patent and/or publication is also enclosed.

Each item of information contained in the Information Disclosure Statement filed herewith was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Statement (37 C.F.R. 1.97(e)(1)). A copy of the communication is enclosed for the Examiner's convenience.

The Examiner is requested to make the citations listed on the enclosed PTO-SB/08A of record in this application.

Applicants would appreciate the Examiner initialing and returning the initialed copy of form PTO-SB/08A, indicating the references have been considered and made of record herein.

No fee is believed due as this statement is being submitted within three months of the mailing date of the enclosed foreign communication. However, if it is determined that fees are required, the Commissioner is hereby authorized to charge any necessary fees associated with this communication or credit any overpayment to Deposit Account No. 50-0815, Order No. RIGIL-023.

Respectfully submitted,

BOZICEVIC, FIELD & FRANCIS LLP

ames S. Keddie, Ph.D., Reg. No. 48,920

Date: December 20, 2006

BOZICEVIC, FIELD & FRANCIS LLP 1900 University Avenue, Suite 200 East Palo Alto, California 94303 Telephone: (650) 327-3400

Facsimile: (650) 327-3231

Please type a plus sign (+) inside this box →

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Substitu	te for form 1449A/PTO	Complete if Known		
outoute		Application Number	10/533,144	
	SUPPLEMENTAL	Filing Date	April 24, 2006	
	INFORMATION DISCLOSURE	First Named Inventor	MASUDA, Esteban	
1	STATEMENT BY APPLICANT	Group Art Unit	1654	
14.14		Examiner Name	TO BE ASSIGNED	
Sheer	(use as many sheets as necessary)			

<u>"</u>	U.S. PATENT DOCUMENTS								
Examin er Initials'	Cite No.1	U.S. Pat Number	ent Documents  Kind Code <sup>2</sup> (if known)	Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY	Pages, columns, lines, Where Relevant Passages or Relevant Figures Appear			

FOREIGN PATENT DOCUMENTS								
Examiner Cite		Fore	Foreign Patent Documents		Name of Patentee or	Date of Publication	Pages, Columns, Lines, Where Relevant	
Initials'	No.1	Office <sup>3</sup>	Number <sup>4</sup>	Kind Code <sup>5</sup> (if known)	Applicant of Cited Documents	of Cited Document MM-DD-YYYY	Passages or Relevant Figures Appear	T <sup>6</sup>

OTHER PRIOR ART—NON PATENT LITERATURE DOCUMENTS							
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), tille of the article (when appropriate), tille of the item (brok, magazine, bounds, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), published, gib and/or country where published.	T				
/C.B./		KINSELLA et al., "Retrovirally Delivered Random Cyclic Peptide Libraries Yield Inhibitors of Interleukin-4 Signaling in Human B Cells", J of Bio Chem, Vol. 277, No. 40 (Oct. 2002), pp 37512-37518.					
		NUTT et al., "Preparation of peptides having atrial natriuretic factor activity identification of a region in alcohol dehydrogenase that binds to .alphacrystallin during chaperone action Recombinant production of proteins in transformed bacteria using chaperonin					
		GroEL, and the chaperonin binding domain", Merck and Co., Inc., USA, (January 1992)					
		CRAIK et al., "Genes encoding insecticidal cystine-knotted macrocyclic proteins of plants and their uses". The University of Queensland, Australia: Latrobe University (May					
		2001)					
			T				

Examiner Signature	/Christina Bradley/	Date Considered							
'EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not									
considered. Include copy of this form with next communication to applicant.									

<sup>&</sup>lt;sup>1</sup>Unique citation designation number. <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.

Burden hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND PEES NO FCO. MORE